This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Alzheimer's Disease & Dementia Conference" (Dementia 2025) June 05-07, 2025 | Hybrid Event has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at dementia@magnusconference.com or call + 1 (702) 988 2320.
A biomarker is a feature that may be measured and assessed objectively as a sign of normal biological or pathological processes, or pharmacological responses to a treatment intervention. A perfect biomarker is one that is repeatable, stable over time, widely available, and directly represents the disease process in question. Alzheimer's disease (AD) is one of the most common dementias among the elderly around the world. A combination of clinical criteria, including a neurological examination, mental status tests, and brain imaging, is used to make a preliminary diagnosis of Alzheimer's disease. However, the diagnosis of AD becomes challenging based on the foregoing clinical tests, especially in individuals with mild or early stages of AD. As a result, biomarkers that exhibit strong symptoms of Alzheimer's disease and also give conclusive diagnosis of early-onset AD become necessary.
Important Alert:
X
Title : Early clinical development of modified P8 for the treatment of alzheimer’s disease
Nazneen N Dewji, Cenna Biosciences Inc, United States
Title : Who cares for the carers
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Memory should be the primary endpoint in early AD
Matthias W Riepe, Ulm University, Germany
Title : Down’s syndrome (trisomy 21) and alzheimer disease: A common medical and scientific fight
London Jacqueline, Paris Diderot University, France
Title : Quality of life children with autism spectrum disorder
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Efficacy of transcranial photobiomodulation in mild cognitive impairment and early alzheimer’s Disease: A randomized controlled study
Hyelim Chun, St.Peter’s General Hospital, Korea, Republic of